Sleep Apnea in Active Adults: The Under-Diagnosed Performance Killer

Educational journalism, not medical advice. Every claim here is checked against its cited sources by editor Tim Bunce — a health writer, not a physician. It isn’t specific to your situation: for health decisions, talk to your own clinician. How we work →

Why athletes get missed

Standard sleep-apnea screening was developed in general medical populations. The classic risk factors — obesity (BMI > 30), male sex, age > 50, large neck circumference, hypertension — identify the majority of community cases. But these factors miss many athletes:

• Lean adults with apnea exist in meaningful numbers. The risk factor isn’t adiposity per se but airway collapse during sleep, which depends on craniofacial anatomy as much as on weight.
• Endurance athletes can have anatomical narrowing — small jaw, recessed chin, large tongue, narrow palate — that produces apnea independent of body composition.
• Heavily-muscled athletes (rugby, American football, weightlifting) can have large neck musculature that adds to airway encroachment during sleep.
• Chronic nasal obstruction (deviated septum, polyps, persistent rhinitis) shifts breathing to mouth-only during sleep, increasing the airway-collapse risk.
• The Epworth Sleepiness Scale — the standard screening tool — relies on subjective daytime sleepiness. Athletes often don’t feel sleepy even with moderate OSA because they’re heavily conditioned to push through fatigue George 2003.

What untreated OSA does to athletes

The published evidence on OSA in athletic populations is smaller than in general populations but consistent:

• Cardiovascular adaptation is blunted. The repeated sympathetic surges from apneic episodes elevate blood pressure and inflammatory markers, reducing the cardiovascular benefit of training Peppard 2013.
• Training adaptation is reduced. Growth hormone and testosterone secretion peak during slow-wave sleep, which apnea interrupts. Athletes with untreated OSA show smaller strength and hypertrophy gains over training cycles.
• Recovery is impaired. Fragmented sleep with apneic events reduces the cumulative slow-wave and REM time that drives glycogen restoration, muscle protein synthesis, and cognitive recovery.
• Cognitive performance declines. Attention, reaction time, and decision-making degrade with untreated OSA — relevant for sports requiring split-second timing.

“Obstructive sleep apnea is under-recognized in athletic populations, particularly in those without classic risk factors. Untreated, it produces measurable decrements in training adaptation, cardiovascular health, and cognitive performance — outcomes the affected athlete is unlikely to attribute to a sleep disorder.”

— Peppard et al., Am J Epidemiol, 2013 view source

The signs to take seriously

Any one of these in an active adult is enough to warrant a sleep evaluation:

• Witnessed apnea — a partner reports breath-holding, choking, or gasping during sleep. The single most specific symptom.
• Loud habitual snoring, particularly if it has worsened over years.
• Morning headaches — often dull, frontal, and resolving within 1-2 hours of waking.
• Unrefreshing sleep despite adequate duration — waking up tired after 8 hours.
• Mid-night awakening with gasping or palpitations.
• Declining training performance with no obvious cause — volume the same, intensity the same, but the times keep dropping.
• Elevated resting heart rate with no other explanation.
• Hypertension treatment that doesn’t respond to standard medications.

Getting tested

• Family doctor referral to a sleep clinic is the standard path. Be specific about which symptoms you have; downplay the “but I exercise a lot so I can’t have it” framing — that’s what causes the under-diagnosis.
• Home sleep apnea tests (HSAT) are now widely available and adequate for diagnosing moderate-severe cases in adults without complex sleep complaints.
• Full polysomnography remains gold standard. Required for definitive diagnosis in complex cases and for some treatment decisions.
• The apnea-hypopnea index (AHI) classifies severity: 5-14 events/hour = mild, 15-29 = moderate, ≥30 = severe.

Treatment options

• CPAP (continuous positive airway pressure): first-line for moderate-severe OSA. Modern devices are quiet, comfortable, and dramatically improve symptoms within weeks. Compliance is the main challenge.
• Oral appliances (mandibular advancement devices): effective for mild-moderate OSA in patients with appropriate dental anatomy. Better tolerated than CPAP by some adults.
• Positional therapy: for adults whose apnea occurs primarily on their back, devices that promote side-sleeping can be sufficient.
• Weight loss helps if elevated BMI is contributing.
• Surgery (uvulopalatopharyngoplasty, jaw advancement) for select anatomical cases. Specialist evaluation required.
• Nasal-passage treatments (septoplasty, polyp removal, allergy management) for adults whose apnea has a significant nasal-obstruction component.

Practical takeaways

• OSA is under-diagnosed in active adults because the standard risk factors (obesity, sedentary lifestyle) miss many athletic cases.
• Untreated OSA blunts training adaptation, recovery, and cardiovascular health. Worth screening for if any of the suspicious signs are present.
• The most specific symptom is witnessed apnea — ask a partner.
• Home sleep tests are widely available and adequate for most moderate-severe cases. Don’t wait for a full lab study.
• CPAP, oral appliances, and positional therapy are all effective treatments depending on severity and anatomy. Treatment dramatically improves training and health outcomes.

How common is this in active, athletic adults?

The article above makes the case that fit people get missed. It is worth putting numbers on how often they are actually affected, because "athletes can't have sleep apnea" is the exact assumption that delays diagnosis. The honest answer is that prevalence depends heavily on the sport, and the strongest data come from one population: large, powerful athletes in collision sports.

Among professional American football players, a scoping review of the published studies found obstructive sleep apnea (OSA) and its symptoms to be consistently more common than in the general public, and dramatically so in the biggest players. One of the reviewed studies of retired players reported sleep-disordered breathing in about half of those screened, with defensive linemen showing roughly 61% prevalence versus 46% for non-linemen Rogers 2017. These are not sedentary men — they are elite, highly trained athletes whose large neck circumference and high body mass push them into the high-risk category despite their fitness. A 2025 study that actually tested college football players with sleep studies found mild-to-moderate OSA in 35% of participants, and the players who screened positive had a significantly higher body mass index (about 29 kg/m²) than those who did not Trikha 2025. The same study noted there is no standard screening protocol in college athletics, which is precisely the gap that lets these cases slip through.

Two cautions keep this honest. First, this evidence is concentrated in linemen and other large-bodied athletes; it does not mean a lean distance runner has the same risk, and the article's point stands that body size is only one of several risk factors. Second, much of the athlete-specific literature is small, observational, and focused on a handful of sports, so prevalence figures should be read as "higher than you'd guess" rather than as precise population rates. The practical takeaway is narrower and more useful: if you carry significant muscle mass, a thick neck, or a higher body weight — common in strength, rugby, and football athletes — your training status does not lower your risk, and it may raise it.

The hormone and metabolism story — with an honest caveat

The section above notes that growth hormone and testosterone peak during slow-wave sleep, and that fragmenting that sleep can blunt training gains. That mechanism is real, but the evidence deserves a more careful telling, because it is easy to oversell.

On the association side, the data are reasonably consistent: a meta-analysis of 24 case-control studies found that men with OSA had significantly lower serum total testosterone than men without it Wang 2023. So the link between untreated apnea and lower testosterone is well documented. The intuitive next step — "treat the apnea with CPAP and testosterone bounces back" — is where the evidence does not cooperate. A meta-analysis pooling 12 studies and 388 men found that CPAP use was not associated with a significant change in total testosterone, and its authors concluded that strategies other than CPAP should be considered for managing low testosterone in men with OSA Cignarelli 2019. In plain terms: low testosterone often travels with OSA, but much of that link is driven by shared factors such as obesity and age rather than by apnea directly switching off the hormone — which is why fixing the breathing alone does not reliably fix the hormone. If low testosterone is a concern, that is a separate conversation to have with your clinician, not something to expect a CPAP machine to solve on its own.

The metabolic side of the story is on firmer ground and matters for any active adult who cares about recovery and long-term health. The repeated drops in blood oxygen during apneic episodes — called intermittent hypoxia — together with fragmented sleep and surges of stress hormones, push the body toward insulin resistance, meaning your cells respond less efficiently to insulin and your blood sugar control worsens. A review in the Journal of Thoracic Disease summarising this literature concluded that OSA is associated with insulin resistance, glucose intolerance, and a higher risk of type 2 diabetes, and that at least part of this link appears to be independent of obesity Kent 2015. For an athlete, impaired glucose handling is not an abstract worry: it sits directly upstream of the glycogen restoration and recovery the article already flags. This is association rather than proven cause-and-effect, and obesity remains a powerful confounder, but the mechanistic case — intermittent hypoxia driving inflammation and disrupted glucose control — is coherent and biologically plausible.

When CPAP isn't the whole answer

The treatment section calls compliance "the main challenge" with CPAP. That is an understatement worth quantifying, because it shapes which treatment is realistic for you. A systematic review spanning roughly twenty years of data found that CPAP non-adherence has stayed stubbornly high — around 34% by one common 7-hour standard — and, strikingly, has not meaningfully improved despite quieter, smarter machines Rotenberg 2016. CPAP works extremely well when it is worn; the problem is that a large minority of people cannot tolerate wearing it through the night, every night.

It also helps to be precise about what CPAP does and does not buy you. The large, randomised SAVE trial (over 2,700 adults with moderate-to-severe OSA and existing cardiovascular disease) found that adding CPAP to usual care significantly reduced snoring and daytime sleepiness and improved quality of life and mood — but did not lower the rate of major cardiovascular events over the study period McEvoy 2016. Two caveats matter: average nightly use in that trial was only about 3.3 hours (below the threshold many believe is needed for cardiovascular benefit), and the participants were not selected for heavy daytime sleepiness. The fair reading is that CPAP is a powerful tool for symptoms, sleep quality, and daytime function — the very things an athlete cares about — but it should not be sold as a guaranteed heart-attack-prevention device on the current evidence.

For people who genuinely cannot tolerate CPAP, the article's list of alternatives can be extended with one evidence-backed option it omits: hypoglossal nerve stimulation, an implanted device (the best-studied is marketed as Inspire) that gently activates the nerve controlling the tongue during sleep to keep the airway open. In its pivotal trial of 126 CPAP-intolerant patients with moderate-to-severe OSA, the device cut the apnea-hypopnea index by about 68% — from roughly 29 to 9 events per hour at twelve months — with serious complications in fewer than 2% of cases Strollo 2014. It is surgery, it is not first-line, and it suits a specific subset of patients identified by a specialist, but for the CPAP-intolerant it is a real, regulated option rather than a fringe gadget. Finally, for active adults there is an appealing adjunct: a 2024 meta-analysis of 12 randomised trials found that structured exercise training (aerobic, with or without resistance work) modestly but significantly reduced AHI by about 7 events per hour and improved peak aerobic fitness, independent of weight loss Lin 2024. Exercise is not a replacement for diagnosing and treating moderate-to-severe apnea — but for an athlete it is a low-risk part of the plan rather than a reason to avoid one.

What the evidence can't tell you yet

Because this is a health topic where overconfidence does harm, it is worth being clear about the edges of the science. Most of what we know about OSA's effect on performance, hormones, and recovery is extrapolated from general clinical populations — often middle-aged, frequently overweight — rather than from trials in healthy athletes, who are simply understudied. The athlete-specific prevalence data lean heavily on collision-sport players and do not transfer cleanly to endurance or lighter-weight athletes Trikha 2025.

Several of the most quoted links are associations rather than proven causes. Lower testosterone tracks with OSA, but treating the apnea does not reliably raise it, which tells us the relationship is more tangled than a simple chain of cause and effect Cignarelli 2019. The metabolic harms are biologically plausible and consistently observed, yet obesity remains a stubborn confounder that researchers have not fully separated out Kent 2015. And the headline cardiovascular question is genuinely unsettled: a major randomised trial did not show that CPAP prevents cardiovascular events, partly because real-world adherence is low McEvoy 2016. None of this is a reason to ignore symptoms — untreated OSA clearly degrades sleep quality and daytime function, and treatment clearly improves them. It is a reason to treat sweeping promises ("fix your apnea and your testosterone, your heart, and your PRs all rebound") with healthy skepticism. If you suspect you have it, the right move is unchanged: get assessed, and make the treatment decision with a sleep clinician who can weigh your specific severity, anatomy, and tolerance rather than chasing a single fix.

References